Key facts
- Eaderm’s last known valuation is $8.1M (Jun 2025).
- It has raised $3.5M; the latest was Later Stage VC ($3.2M) in Jun 2025.
- Notable investors include ANRI, UntroD, Hiromitsu Nakauchi, Rohto Pharmaceutical.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Eaderm
- ·The full record, as it builds
Funding rounds
No funding rounds for Eaderm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eaderm
Developer of therapeutic drugs designed for pain associated with skin and hair diseases. The company uses stem cell control technology to develop new therapeutic drugs and quasi-drugs that simultaneously realize healthy regeneration and disease improvement by stem cells by searching for substances that maintain the quality of tissue stem cell pools, enabling patients to recover from intractable skin and hair diseases and changes in appearance.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 3
- Website
- eaderm.com/
- Ownership
- Privately Held (backing)
Eaderm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eaderm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eaderm in its N-PORT filings yet. We sweep new filings monthly.